Friday, October 31, 2025 10/31/2025

Assessment of Transdermal Drug Product Quality and Performance Attributes via Enhanced Virtual Bioequivalence Simulations

Award Number: U01FD006526
ORGANIZATION: FOOD AND DRUG ADMINISTRATION
OPDIV: FDA
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/01/2018
PERIOD OF PERFORMANCE END DATE: 08/31/2021

Group Awards By:

View Award Description

Assessment of Transdermal Drug Product Quality and Performance Attributes via Enhanced Virtual Bioequivalence Simulations - Dermal Formulation Quality by Design Project Abstract The Office of Generic Drugs (OGD) is tasked, among other things, with reviewing sponsor applications for dermal dosage forms that purport to be bioequivalent to the approved formulations for the same drug. Sponsor companies want to have high confidence that applications they submit for dosage forms thought to be bioequivalent will receive favorable reviews. Software that embodies physiologically based pharmacokinetics (PBPK) and mechanistic absorption model (MAM) and accounts for formulation effects in predicting the local drug concentration in the skin as well as concentration in systemic circulation can be a useful tool to reduce the time and expense involved in designing new generic formulations and assessing their potential to be bioequivalent to approved dosage forms by industry and regulatory scientists. Developing a state-of-the-art capability for dermal MAM/PBPK software requires an extensive knowledge base to serve as the scientific foundation, talented scientists to apply the knowledge base in the development of useful equations and logic suitable for software, high-level computer programming skills to encode the equations and logic into user-friendly software, and experienced scientists to test, validate, document, and support the software for use by others not involved in its development. This proposed project will advance the state-of-the-art for dermal MAM/PBPK modeling to include the ability to identify and quantify drug-product-specific critical quality and performance attributes of transdermal dosage forms. This will be achieved through a combination of expanding the existing knowledge base and compiling a database of critical product quality and performance attributes for transdermal formulations, as well as enhancing the models in the Transdermal Compartmental Absorption and Transit™ (TCAT™) MAM/PBPK model within the GastroPlus™ software program to account for these formulation attributes in the assessment of virtual bioequivalence between brand and generic drug products. By basing the final software program on the well-established and validated TCAT model, which is in use at the FDA and within the pharmaceutical innovator and generic industries today, we will be able to focus project resources entirely on advancing the capabilities of the model rather than having to develop new code for the core program and its many support capabilities (e.g., integration, plotting, Parameter Sensitivity Analysis, Population Simulations). Throughout the effort, we will maintain close contact with the FDA program manager and the Consortium for Dermal Absorption Modeling (CDAM) that we will form with our collaboration partners and the FDA to ensure the project team focuses on model development and new experimental work. This will result in developing the optimum software capabilities to implement dermal product Quality by Design (QbD) and virtual bioequivalence assessment, within the scope of the project.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2023 ( Subtotal = $0 )
2023	2019	SIMULATIONS PLUS INC	42505 10TH ST W STE 103	LANCASTER	CA	93534	LOS ANGELES	USA	Food and Drug Administration Research	000	2	12/5/2022	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2020 ( Subtotal = $0 )
2020	2019	SIMULATIONS PLUS, INC.	42505 10TH ST W	LANCASTER	CA	93534	LOS ANGELES	USA	Food and Drug Administration Research	000	2	8/7/2020	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2019 ( Subtotal = $250,000 )
2019	2019	SIMULATIONS PLUS, INC.	42505 10TH ST W	LANCASTER	CA	93534	LOS ANGELES	USA	Food and Drug Administration Research	000	2	8/14/2019	NON-COMPETING CONTINUATION	$250,000
														Subtotal = $250,000

Issue Date FY: 2018 ( Subtotal = $253,440 )
2018	2018	SIMULATIONS PLUS, INC.	42505 10TH STREET W	LANCASTER	CA	93534	LOS ANGELES	USA	Food and Drug Administration Research	000	1	8/28/2018	NEW	$253,440
2018	2018	SIMULATIONS PLUS, INC.	42505 10TH STREET W	LANCASTER	CA	93534	LOS ANGELES	USA	Food and Drug Administration Research	001	1	8/29/2018	NEW	$0
														Subtotal = $253,440

Grand Total All Awards = $503,440

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Assessment of Transdermal Drug Product Quality and Performance Attributes via Enhanced Virtual Bioequivalence Simulations

Award Number: U01FD006526

ORGANIZATION: FOOD AND DRUG ADMINISTRATION

OPDIV: FDA

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/01/2018

PERIOD OF PERFORMANCE END DATE: 08/31/2021

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer